Loading
A phase 3 trial of Motixafortide, Filgrastim in multiple myeloma, run by Guangzhou Gloria Biosciences Co., Ltd., now recruiting.
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients is a phase 3 interventional study registered as NCT06514508 by Guangzhou Gloria Biosciences Co., Ltd., with 60 participants planned, started 2025-12-01 and due to reach its primary completion in 2026-09-11. Interventions recorded: Motixafortide+G-CSF, Placebo+G-CSF. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Motixafortide, Filgrastim (G-CSF), Multiple myeloma.
Shares Filgrastim (G-CSF), Multiple myeloma.
Shares Filgrastim (G-CSF), Multiple myeloma.
Shares Motixafortide, Filgrastim (G-CSF), Multiple myeloma.